Display Settings:

Format

Send to:

Choose Destination

    Curr Opin Investig Drugs. 2002 Aug;3(8):1196-8.

    ART-123 Asahi Kasei.

    Khorchidi S, Bantleon R, Kehlbach R, Tepe G, Wiskirchen J, Duda SH.

    Department of Radiology, University of Tübingen, Germany. sascha.khorchidi@uni-tuebingen.de

    Asahi Kasei is developing a recombinant thrombomodulin (ART-123), a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting disorders, such as disseminated intravascular thromboembolism [169907]. By September 2000, it had entered phase III trials [383525]. A patent, US-05916874, claiming a method for treating liver injury and whose composition comprises a thrombomodulin, was published in 1999 by the company.

    PMID: 12211414 [PubMed - indexed for MEDLINE]

    Supplemental Content